Huijberts et al. have conceived phase I/II study to determine the efficacy of sequential treatment with vorinostat and BRAF inhibitor/MEK inhibitor in resistant BRAF V600E mutant melanoma (NCT02836548) [78]. Here, MAP2K7 is linked to melanoma.